New findings could have implications for the use of salvage therapies.
Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.
In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
A recent systematic review and meta-analysis provides the most up-to-date evidence for performance of triplet therapy compared with API-based doublets in mCSPC.
Prostate cancer-specific mortality was low for men randomly assigned to active monitoring, prostatectomy, or radiotherapy.